Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016081 · ClinicalTrials.gov registry record · Phase 3
Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation
A Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00016081: Completed Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
NCT00016081 is a Phase 3 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016081, a Phase 3 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective than standard therapy in preventing pneumonia in patients who have respiratory syncytial virus (RSV) infection following stem cell transplantation. PURPOSE: Randomized phase III trial to compare the effectiveness of ribavirin with that of standard therapy in preventing pneumonia in patients who have RSV infection following stem cell transplantation.
Interventions
- DRUG ribavirin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-03 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
What the finished NCT00016081 record still lists
NCT00016081 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ribavirin is the first listed.
NCT00016081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00016081 about?
NCT00016081 is a clinical study titled "Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation". RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective than standard therapy in preventing pneumonia in patients who have respiratory syncytial virus (RSV) infection following stem cell transplantation. PURPOSE: Ran...
What is the current status of trial NCT00016081?
This trial is currently completed. It is a Phase 3 study. The study started on 1998-03. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00016081?
The interventions under investigation include: ribavirin (DRUG).
Who is sponsoring clinical trial NCT00016081?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia